WallStSmart
MIRM

Mirum Pharmaceuticals Inc

NASDAQ: MIRM · HEALTHCARE · BIOTECHNOLOGY

$106.17
+1.07% today

Updated 2026-06-05

Market cap
$6.06B
P/E ratio
P/S ratio
10.64x
EPS (TTM)
$-13.60
Dividend yield
52W range
$48 – $115
Volume
1.0M

Mirum Pharmaceuticals Inc (MIRM) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20182019202020212022202320242025
Operating cash flow$-373000.00$-39.36M$-89.08M$-132.76M$-120.14M$-70.94M$10.32M$55.83M
Capital expenditures$7.50M$281000.00$225000.00$19.02M$278000.00$20.11M$993000.00$954000.00
Depreciation
Stock-based comp$51000.00$6.07M$12.55M$23.09M$27.01M$35.02M$48.44M$71.42M
Free cash flow$-7.87M$-39.64M$-89.30M$-151.78M$-120.41M$-91.05M$9.33M$54.87M
Investing cash flow
Financing cash flow
Dividends paid$0.00$0.00$5.55M
Share repurchases
Debt repayment
Net change in cash$0.00$130.09M$-10.74M$-3.35M

Frequently asked questions

What is Mirum Pharmaceuticals Inc's revenue?

Mirum Pharmaceuticals Inc's trailing twelve-month revenue is $569.61M, and consensus projects about $1.58B by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is MIRM?

In its most recent fiscal year, MIRM ran a gross margin of 80.71%, an operating margin of -4.25%, and a net margin of -4.48%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does MIRM generate?

MIRM produced $54.87M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is MIRM's balance sheet healthy?

MIRM holds $296.68M in cash and equivalents against $309.80M in long-term debt, on $314.69M of shareholder equity. That debt is best read against the cash flow the business throws off each year.